Hydroxyurea Nitrosylates and Activates Soluble Guanylyl Cyclase in Human Erythroid Cells

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2007 Nov 13

PMID 17993617

Citations 43

Authors

Vladan P cokic

Silvana A Andric

Stanko S Stojilkovic

Constance T Noguchi

Alan N Schechter

Affiliations

Soon will be listed here.

Abstract

Hydroxyurea, a drug widely used for treating myeloproliferative diseases, has also been approved for the treatment of sickle cell disease by raising fetal hemoglobin (HbF). We have shown that nitric oxide (NO) and the soluble guanylyl cyclase (sGC) pathways are involved in hydroxyurea induction of HbF levels in erythroid progenitor cells (EPCs). We demonstrate now that during erythroid differentiation, endothelial NO synthase mRNA and protein levels decline steadily, as does the production of NO derivatives and cyclic adenosine monophosphate (cAMP) levels, but guanosine 3',5'-cyclic monophosphate (cGMP) levels are stable. Hydroxyurea increased intracellular cGMP levels and cAMP levels in EPCs. The NO donor, DEANONOate, induced much higher cGMP levels, but reduced cAMP levels. Hydroxyurea (1 mM) induced production of approximately 45 pM cGMP/minute/ng of purified sGC, similar to induction by 1 muM DEANONOate. We found that hydroxyurea and ProliNONOate produced iron-nitrosyl derivatives of sGC. Thus, we confirm that hydroxyurea can directly interact with the deoxy-heme of sGC, presumably by a free-radical nitroxide pathway, and activate cGMP production. These data add to an expanding appreciation of the role of hydroxyurea as an inducer of the NO/cGMP pathway in EPCs. These mechanisms may also be involved in the cytostatic effects of hydroxyurea, as well as the induction of HbF.

Citing Articles

Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission.

Piel F, Rees D, DeBaun M, Nnodu O, Ranque B, Thompson A Lancet Haematol. 2023; 10(8):e633-e686.

PMID: 37451304 PMC: 11459696. DOI: 10.1016/S2352-3026(23)00096-0.

Efficacy of Hydroxyurea in Transfusion-Dependent Major β-Thalassemia Patients: A Meta-Analysis.

Hatamleh M, Chenna V, Contractor H, Krishna Mohan G, Tirumandyam G, Dammas N Cureus. 2023; 15(4):e38135.

PMID: 37252463 PMC: 10213992. DOI: 10.7759/cureus.38135.

Outcomes of Hydroxyurea Accessed via Various Means and Barriers Affecting Its Usage Among Children with Sickle Cell Anaemia in North-Western Tanzania.

Ambrose E, Kidenya B, Charles M, Ndunguru J, Jonathan A, Makani J J Blood Med. 2023; 14:37-47.

PMID: 36712580 PMC: 9875573. DOI: 10.2147/JBM.S380901.

Nitric Oxide Synthase Dependency in Hydroxyurea Inhibition of Erythroid Progenitor Growth.

Suboticki T, Ajtic O, dikic D, Santibanez J, Tosic M, cokic V Genes (Basel). 2021; 12(8).

PMID: 34440315 PMC: 8391407. DOI: 10.3390/genes12081145.

Red Blood Cell and Endothelial eNOS Independently Regulate Circulating Nitric Oxide Metabolites and Blood Pressure.

Leo F, Suvorava T, Heuser S, Li J, LoBue A, Barbarino F Circulation. 2021; 144(11):870-889.

PMID: 34229449 PMC: 8529898. DOI: 10.1161/CIRCULATIONAHA.120.049606.

References

Shami P, Moore J, Gockerman J, Hathorn J, Misukonis M, Weinberg J . Nitric oxide modulation of the growth and differentiation of freshly isolated acute non-lymphocytic leukemia cells. Leuk Res. 1995; 19(8):527-33. DOI: 10.1016/0145-2126(95)00013-e. View

Chen L, Mehta J . Evidence for the presence of L-arginine-nitric oxide pathway in human red blood cells: relevance in the effects of red blood cells on platelet function. J Cardiovasc Pharmacol. 1998; 32(1):57-61. DOI: 10.1097/00005344-199807000-00009. View

Kwon N, Stuehr D, Nathan C . Inhibition of tumor cell ribonucleotide reductase by macrophage-derived nitric oxide. J Exp Med. 1991; 174(4):761-7. PMC: 2118959. DOI: 10.1084/jem.174.4.761. View

Kim-Shapiro D, King S, Shields H, Kolibash C, Gravatt W, Ballas S . The reaction of deoxy-sickle cell hemoglobin with hydroxyurea. Biochim Biophys Acta. 1999; 1428(2-3):381-7. DOI: 10.1016/s0304-4165(99)00071-9. View

Huang J, Hadimani S, Rupon J, Ballas S, Kim-Shapiro D, King S . Iron nitrosyl hemoglobin formation from the reactions of hemoglobin and hydroxyurea. Biochemistry. 2002; 41(7):2466-74. DOI: 10.1021/bi011470o. View

Smith R, Li J, Noguchi C, Schechter A . Quantitative PCR analysis of HbF inducers in primary human adult erythroid cells. Blood. 2000; 95(3):863-9. View

Cosby K, Partovi K, Crawford J, Patel R, Reiter C, Martyr S . Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med. 2003; 9(12):1498-505. DOI: 10.1038/nm954. View

LEPOIVRE M, Flaman J, Bobe P, Lemaire G, Henry Y . Quenching of the tyrosyl free radical of ribonucleotide reductase by nitric oxide. Relationship to cytostasis induced in tumor cells by cytotoxic macrophages. J Biol Chem. 1994; 269(34):21891-7. View

cokic V, Beleslin-Cokic B, Tomic M, Stojilkovic S, Noguchi C, Schechter A . Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells. Blood. 2006; 108(1):184-91. DOI: 10.1182/blood-2005-11-4454. View

10.

Kuroyanagi Y, Kaneko Y, Muta K, Park B, Moi P, Ausenda S . cAMP differentially regulates gamma-globin gene expression in erythroleukemic cells and primary erythroblasts through c-Myb expression. Biochem Biophys Res Commun. 2006; 344(3):1038-47. DOI: 10.1016/j.bbrc.2006.03.203. View

11.

Sharma V, Traylor T, Gardiner R, Mizukami H . Reaction of nitric oxide with heme proteins and model compounds of hemoglobin. Biochemistry. 1987; 26(13):3837-43. DOI: 10.1021/bi00387a015. View

12.

Artz J, TOADER V, Zavorin S, Bennett B, Thatcher G . In vitro activation of soluble guanylyl cyclase and nitric oxide release: a comparison of NO donors and NO mimetics. Biochemistry. 2001; 40(31):9256-64. DOI: 10.1021/bi002885x. View

13.

Baumann R, Blass C, Gotz R, Dragon S . Ontogeny of catecholamine and adenosine receptor-mediated cAMP signaling of embryonic red blood cells: role of cGMP-inhibited phosphodiesterase 3 and hemoglobin. Blood. 1999; 94(12):4314-20. View

14.

Kollau A, Beretta M, Gorren A, Russwurm M, Koesling D, Schmidt K . Bioactivation of nitroglycerin by ascorbate. Mol Pharmacol. 2007; 72(1):191-6. DOI: 10.1124/mol.107.035642. View

15.

Sakano K, Oikawa S, Hasegawa K, Kawanishi S . Hydroxyurea induces site-specific DNA damage via formation of hydrogen peroxide and nitric oxide. Jpn J Cancer Res. 2001; 92(11):1166-74. PMC: 5926660. DOI: 10.1111/j.1349-7006.2001.tb02136.x. View

16.

Kleinbongard P, Schulz R, Rassaf T, Lauer T, Dejam A, Jax T . Red blood cells express a functional endothelial nitric oxide synthase. Blood. 2005; 107(7):2943-51. DOI: 10.1182/blood-2005-10-3992. View

17.

Ikuta T, Ausenda S, Cappellini M . Mechanism for fetal globin gene expression: role of the soluble guanylate cyclase-cGMP-dependent protein kinase pathway. Proc Natl Acad Sci U S A. 2001; 98(4):1847-52. PMC: 29345. DOI: 10.1073/pnas.98.4.1847. View

18.

Kang E, Ford K, Grokulsky G, Wang Y, Chiang T, Acchiardo S . Normal circulating adult human red blood cells contain inactive NOS proteins. J Lab Clin Med. 2000; 135(6):444-51. DOI: 10.1067/mlc.2000.106805. View

19.

Inoue A, Kuroyanagi Y, Terui K, Moi P, Ikuta T . Negative regulation of gamma-globin gene expression by cyclic AMP-dependent pathway in erythroid cells. Exp Hematol. 2004; 32(3):244-53. DOI: 10.1016/j.exphem.2003.12.006. View

20.

Shiva S, Huang Z, Grubina R, Sun J, Ringwood L, MacArthur P . Deoxymyoglobin is a nitrite reductase that generates nitric oxide and regulates mitochondrial respiration. Circ Res. 2007; 100(5):654-61. DOI: 10.1161/01.RES.0000260171.52224.6b. View